Opinion|Videos|November 4, 2024

Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

Panelists discuss how various approved and investigational FcRn-targeting agents differ in their mechanisms of action for treating generalized myasthenia gravis (gMG).

Video content above is prompted by the following:

  • A number of agents targeting the neonatal Fc receptor (FcRn) have recently been approved or are under investigation to treat gMG. What are the differences regarding mechanism of action among the following approved or investigational FcRn-targeting agents?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME